UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER ENDED 30TH JUNE, 2004
(RS. IN LACS)
PARTICULARS
3 Months
30.06.2004
Unaudited
3 Months
30.06.2003
Unaudited
Year Ending
31.3.2004
Audited
Year Ending
31.3.2003
Audited
Net Sales/Operational Income
4400.00
3819.10
16652.16
14480.65
Others Income
24.37
26.98
193.11
72.46
TOTAL EXPENDITURE:
3764.52
3425.76
14688.67
12898.19
Increase/(decrease) in stock in trade
328.64
33.10
675.87
-178.49
Consumption of Raw Material
3074.23
2820.96
12256.41
10723.15
Staff Cost
89.93
51.76
245.21
200.87
Other expenditure
929.00
586.14
2862.92
1795.69
Interest
202.82
188.55
708.31
675.85
Depreciation
89.69
60.73
278.67
233.45
Profit(+)/Loss(-) before tax
367.33
171.04
1169.62
745.62
Provision for taxation
28.80
11.44
75.48
60.10
Provision for deferred tax
52.58
21.20
324.98
153.43
Net Profit/Loss
285.95
138.40
769.17
532.09
Paid up Equity Share Capital
-
-
1561.37
1304.63
Reserve
-
-
3581.75
2551.66
EPS (Rs) : (Not> Annualised)
- Basic
- Diluted
1.83
1.71
1.06
1.06
5.24
4.87
4.78
4.78
Aggregate of non promoters shareholding
No. of shares
% of shareholding
-
-
9779594
62.63%
7124289
54.61%
Notes:
a) During the quarter under review, the net
profit rose by 106% and the Income from operation rose by 15% as compared to the
corresponding quarter of the previous year.
b)During the quarter, the exports increased
by 53% over the corresponding quarter of the previous year .
c)During the Quarter, Company Launched 'Nitazoxanide',
an Anti-Diarroheal molecule for the first time in Asia besides launching three other
new molecules viz. Ezetimibe , Rosuvastatin and Acamprosate
d)The Company is exclusively in the Pharmaceutical
business segment.
e)Summary of Investor complaints
Opening: 1, Received during the quarter: 3, Resolved : 3, Closing : 1.
f) The above financial results were taken on
record by the Board at its meeting held on 21st July, 2004.
For Ind-Swift Laboratories Limited
Sd/-
Sd/-
Place:Chandigarh
(N.R.MUNJAL)
(V.K.MEHTA)
Date:30.06.2004
Managing Director
Jt.Managing Director
To know about our Formulation Division, please visit us at
Ind-Swift Limited, our other group company.
